9-ING-41
产品说明书
 |
同义名 : | Elraglusib |
| CAS号 : | 1034895-42-5 | |
| 货号 : | A1264331 | |
| 分子式 : | C22H13FN2O5 | |
| 纯度 : | 99%+ | |
| 分子量 : | 404.347 | |
| MDL号 : | MFCD16495778 | |
| 存储条件： |
Pure form Inert atmosphere,Room Temperature In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 50 mg/mL(123.66 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Glycogen synthase kinase-3 (GSK-3), a serine/threonine kinase, is a master regulator of neural progenitor homeostasis, integrating multiple proliferation, and differentiation signals, and thus has been focused on as a potential target in neuroblastoma. 9-ING-41, a potent and selective small-molecule GSK-3 inhibitor, is active in neuroblastoma. In cell viability assay, 9-ING-41 inhibited the growth of SK-N-DZ and SK-N-BE(2) neuroblastoma cells with GI50s among 50–100 nM. 9-ING-41 (0.1–1 µM) inhibited GSK-3 leading to a decreased expression of the NF-κB target XIAP and significant apoptosis in neuroblastoma cells[1]. Teretment with low doses of 9-ING-41 for 48 hours specifically induced lymphoma cell apoptosis without affecting normal lymphocytes[2]. In vivo, 9-ING-41 (70 mg/kg) potentiated the effects of CPT-11 (5 mg/kg) in growth inhibition of neuroblastoma xenograft tumors[1]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.47mL 0.49mL 0.25mL |
12.37mL 2.47mL 1.24mL |
24.73mL 4.95mL 2.47mL |
| 参考文献 |
|---|